Comparative Pharmacology
Head-to-head clinical analysis: TAPENTADOL HYDROCHLORIDE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAPENTADOL HYDROCHLORIDE versus WESTADONE.
TAPENTADOL HYDROCHLORIDE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition. It has no significant activity at other opioid receptors and minimal serotonergic effects.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Adults: Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain, not to exceed 600 mg per day. Extended-release tablets: 50 mg orally twice daily, titrated to a maximum of 500 mg per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
4 hours (terminal elimination half-life, clinically relevant for dosing interval every 4-6 hours; prolonged in moderate-severe hepatic impairment [up to 6.4 hours] and moderate-severe renal impairment [up to 7.5 hours]).
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Primarily renal (95% excreted in urine; 30% as unchanged tapentadol, 55% as tapentadol-O-glucuronide, and 10% as minor metabolites). Fecal elimination accounts for <3%.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category A/B
Category C
Opioid Agonist
Opioid Agonist